Caribou Biosciences, Inc.
CRBU
Rank in Stocks
#23177
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm... Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Share Price
$0.4198
Last synced: 2026-11-09
Market Cap
$45.01M
Change (1 day)
-6.44%
Change (1 year)
-81.26%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Caribou Biosciences, Inc. (CRBU)
Category
Healthcare
Operating Margin for Caribou Biosciences, Inc. (CRBU)
Operating Margin as of November 2026 TTM: -1,090.90%
According to Caribou Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is -1,090.90%. At the end of 2025 the company had an operating margin of -1,220.49%.
Operating Margin history for Caribou Biosciences, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,090.90% | -10.62% |
| 2025 | -1,220.49% | -26.79% |
| 2024 | -1,667.16% | 395.25% |
| 2023 | -336.63% | -56.18% |
| 2022 | -768.17% | 10.08% |
| 2021 | -697.84% | 138.79% |
| 2020 | -292.24% | -50.69% |
| 2019 | -592.69% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.86% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.03% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Caribou Biosciences, Inc.'s operating margin
What is Caribou Biosciences, Inc.'s operating margin?
Caribou Biosciences, Inc.'s operating margin is -1,090.90%, as of Nov 2026.
What was Caribou Biosciences, Inc.'s operating margin in 2025?
In 2025, Caribou Biosciences, Inc.'s operating margin was -1,220.49%, compared with -1,667.16% in 2024.
How has Caribou Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Caribou Biosciences, Inc.'s operating margin was highest in 2020 (-292.24%) and lowest in 2024 (-1,667.16%).
How does Caribou Biosciences, Inc.'s operating margin compare with similar companies?
Caribou Biosciences, Inc.'s operating margin (-1,090.90%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.